This page in English

Katarina Le Blanc

Professor/specialistläkare

Organisatorisk tillhörighet

Avdelningen för Klinisk Immunologi o Transfusionsmedicin

Institution

Institutionen för laboratoriemedicin (LABMED), H5

Besöksadress : Karolinska Universitetssjukhuset, Huddinge F79 14186 Stockholm
Postadress : Institutionen för laboratoriemedicin (LABMED), H5, Avdelningen för Klinisk Immunologi o Transfusionsmedicin, Karolinska Universitetssjukhuset, Huddinge F79 14186 Stockholm
Leveransadress : Karolinska Universitetssjukhuset, Huddinge F79 14186 Stockholm

Om mig

Professor i klinisk stamcellsforskning.

Forskningsbeskrivning

Katarina Le Blanc group (på engelska).

Publikationer

Heparinization of cell surfaces with short peptide-conjugated PEG-lipid regulates thromboinflammation in transplantation of human MSCs and hepatocytes
Asif S, Ekdahl Kn, Fromell K, Gustafson E, Barbu A, Le Blanc K, et al
Acta biomaterialia 2016;35():194-205

International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials
Galipeau J, Krampera M, Barrett J, Dazzi F, Deans Rj, Debruijn J, et al
Cytotherapy 2016;18(2):151-9

Mesenchymal Stromal Cells Disrupt mTOR-Signaling and Aerobic Glycolysis During T-Cell Activation
Bottcher M, D Hofmann A, Bruns H, Haibach M, Loschinski R, Saul D, et al
Stem cells (Dayton, Ohio) 2016;34(2):516-21

Wnt/β-Catenin Stimulation and Laminins Support Cardiovascular Cell Progenitor Expansion from Human Fetal Cardiac Mesenchymal Stromal Cells
Mansson-broberg A, Rodin S, Bulatovic I, Ibarra C, Lofling M, Genead R, et al
Stem cell reports 2016;6(4):607-17

Amniotic fluid - a source for clinical therapeutics in the newborn?
Ekblad A, Qian H, Westgren M, Le Blanc K, Fossum M, Gotherstrom C
Stem cells and development 2015;24(12):1405-14

Enhanced oral healing following local mesenchymal stromal cell therapy
Garming-legert K, Tour G, Sugars R, Von Bahr L, Davies Lc, Le Blanc K
Oral oncology 2015;51(12):e97-9

Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting
Wiklander Op, Nordin Jz, O'loughlin A, Gustafsson Y, Corso G, Mager I, et al
Journal of extracellular vesicles 2015;4():26316-

Immunogenicity of virosomal adjuvanted trivalent influenza vaccination in allogeneic stem cell transplant recipients
Ambati A, Einarsdottir S, Magalhaes I, Poiret T, Bodenstein R, Leblanc K, et al
Transplant infectious disease : an official journal of the Transplantation Society 2015;17(3):371-9

Increased incidence of chronic GvHD and CMV disease in patients with vitamin D deficiency before allogeneic stem cell transplantation
Von Bahr L, Blennow O, Alm J, Bjorklund A, Malmberg Kj, Mougiakakos D, et al
Bone marrow transplantation 2015;50(9):1217-23

In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome
Simonson Oe, Mougiakakos D, Heldring N, Bassi G, Johansson Hj, Dalen M, et al
Stem cells translational medicine 2015;4(10):1199-213

Mesenchymal stromal cells and the innate immune response
Le Blanc K, Davies Lc
Immunology letters 2015;168(2):140-6

Mesenchymal stromal cells support endothelial cell interactions in an intramuscular islet transplantation model
Fransson M, Brannstrom J, Duprez I, Essand M, Le Blanc K, Korsgren O, et al
Regenerative medicine research 2015;3():1-

Mesenchymal stromal cells to halt the progression of type 1 diabetes?
Carlsson Po, Korsgren O, Le Blanc K
Current diabetes reports 2015;15(7):46-

MSCs: Scientific Support for Multiple Therapies
Pittenger Mf, Le Blanc K, Phinney Dg, Chan Jk
Stem cells international 2015;2015():280572-

Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells
Carlsson Po, Schwarcz E, Korsgren O, Le Blanc K
Diabetes 2015;64(2):587-92

SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking
Alexander T, Bondanza A, Muraro Pa, Greco R, Saccardi R, Daikeler T, et al
Bone marrow transplantation 2015;50(2):173-80

Stromal cell-mediated glycolytic switch in CLL cells involves Notch-c-Myc signaling
Jitschin R, Braun M, Qorraj M, Saul D, Le Blanc K, Zenz T, et al
Blood 2015;125(22):3432-6

Therapeutic Potential of Multipotent Mesenchymal Stromal Cells and Their Extracellular Vesicles
Heldring N, Mager I, Wood Mj, Le Blanc K, Andaloussi Se
Human gene therapy 2015;26(8):506-17

CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs
Jitschin R, Braun M, Buttner M, Dettmer-wilde K, Bricks J, Berger J, et al
Blood 2014;124(5):750-60

Defined serum-free media for in vitro expansion of adipose-derived mesenchymal stem cells
Al-saqi Sh, Saliem M, Asikainen S, Quezada Hc, Ekblad A, Hovatta O, et al
Cytotherapy 2014;16(7):915-26

Do ABO blood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells?
Moll G, Hult A, Von Bahr L, Alm Jj, Heldring N, Hamad Oa, et al
PloS one 2014;9(1):e85040-

Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?
Moll G, Alm Jj, Davies Lc, Von Bahr L, Heldring N, Stenbeck-funke L, et al
Stem cells (Dayton, Ohio) 2014;32(9):2430-42

Intranasal delivery of central nervous system-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis
Fransson M, Piras E, Wang H, Burman J, Duprez I, Harris Ra, et al
Immunology 2014;142(3):431-41

Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience
Gotherstrom C, Westgren M, Shaw Sw, Astrom E, Biswas A, Byers Ph, et al
Stem cells translational medicine 2014;3(2):255-64

White paper on how to go forward with cell-based advanced therapies in Europe
Erben Rg, Silva-lima B, Reischl I, Steinhoff G, Tiedemann G, Dalemans W, et al
Tissue engineering. Part A 2014;20(19-20):2549-54

Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures
Yu D, Jin C, Ramachandran M, Xu J, Nilsson B, Korsgren O, et al
PloS one 2013;8(1):e54952-

Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation
Jitschin R, Mougiakakos D, Von Bahr L, Volkl S, Moll G, Ringden O, et al
Stem cells (Dayton, Ohio) 2013;31(8):1715-25

A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation
Ringden O, Erkers T, Aschan J, Garming-legert K, Le Blanc K, Hagglund H, et al
Journal of internal medicine 2013;274(2):153-62

Human embryonic stem cell-derived mesenchymal stroma cells (hES-MSCs) engraft in vivo and support hematopoiesis without suppressing immune function: implications for off-the shelf ES-MSC therapies
Li O, Tormin A, Sundberg B, Hyllner J, Le Blanc K, Scheding S
PloS one 2013;8(1):e55319-

Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation
Mougiakakos D, Jitschin R, Von Bahr L, Poschke I, Gary R, Sundberg B, et al
Leukemia 2013;27(2):377-88

MSCs: science and trials
Fibbe We, Dazzi F, Leblanc K
Nature medicine 2013;19(7):812-3

Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease
Ball Lm, Bernardo Me, Roelofs H, Van Tol Mj, Contoli B, Zwaginga Jj, et al
British journal of haematology 2013;163(4):501-9

Myeloid-derived suppressor cells in allogeneic hematopoietic stem cell transplantation A double-edged sword?
Le Blanc K, Jitschin R, Mougiakakos D
ONCOIMMUNOLOGY 2013;2(7):-

Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation
Von Bahr L, Batsis I, Moll G, Hagg M, Szakos A, Sundberg B, et al
Stem cells (Dayton, Ohio) 2012;30(7):1575-8

Are therapeutic human mesenchymal stromal cells compatible with human blood?
Moll G, Rasmusson-duprez I, Von Bahr L, Connolly-andersen Am, Elgue G, Funke L, et al
Stem cells (Dayton, Ohio) 2012;30(7):1565-74

Donor cell-derived acute myeloid leukemia after second allogenic cord blood transplantation in a patient with Fanconi anemia
Gustafsson B, Moell J, Leblanc K, Barbany G, Soderhall S, Winiarski J
Pediatric transplantation 2012;16(6):E241-5

Factors with an impact on chimerism development and long-term survival after umbilical cord blood transplantation
Berglund S, Le Blanc K, Remberger M, Gertow J, Uzunel M, Svenberg P, et al
Transplantation 2012;94(10):1066-74

Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy
Von Bahr L, Sundberg B, Lonnies L, Sander B, Karbach H, Hagglund H, et al
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2012;18(4):557-64

Multipotent mesenchymal stromal cells and the innate immune system
Le Blanc K, Mougiakakos D
Nature reviews. Immunology 2012;12(5):383-96

Oral mucosal progenitor cells are potently immunosuppressive in a dose-independent manner
Davies Lc, Lonnies H, Locke M, Sundberg B, Rosendahl K, Gotherstrom C, et al
Stem cells and development 2012;21(9):1478-87

Primary mesenchymal stem and progenitor cells from bone marrow lack expression of CD44 protein
Qian H, Le Blanc K, Sigvardsson M
The Journal of biological chemistry 2012;287(31):25795-807

Targeted intra-arterial transplantation of stem cells to the injured CNS is more effective than intravenous administration: engraftment is dependent on cell type and adhesion molecule expression
Lundberg J, Sodersten E, Sundstrom E, Le Blanc K, Andersson T, Hermanson O, et al
Cell transplantation 2012;21(1):333-43

Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements
Doorn J, Moll G, Le Blanc K, Van Blitterswijk C, De Boer J
Tissue engineering. Part B, Reviews 2012;18(2):101-15

Treatment of familial hemophagocytic lymphohistiocytosis with third-party mesenchymal stromal cells
Mougiakakos D, Machaczka M, Jitschin R, Klimkowska M, Entesarian M, Bryceson Yt, et al
Stem cells and development 2012;21(17):3147-51

Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation
Forslow U, Blennow O, Leblanc K, Ringden O, Gustafsson B, Mattsson J, et al
European journal of haematology 2012;89(3):220-7

Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation
Bernardo Me, Ball Lm, Cometa Am, Roelofs H, Zecca M, Avanzini Ma, et al
Bone marrow transplantation 2011;46(2):200-7

Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways
Gotherstrom C, Lundqvist A, Duprez Ir, Childs R, Berg L, Le Blanc K
Cytotherapy 2011;13(3):269-78

Improved survival after allogeneic haematopoietic stem cell transplantation in recent years
Ringden O, Ackefors M, Berglund S, Blennow O, Dahllof G, Dlugosz A, et al
BONE MARROW TRANSPLANTATION 2011;:S167-S168

Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study
Remberger M, Ackefors M, Berglund S, Blennow O, Dahllof G, Dlugosz A, et al
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2011;17(11):1688-97

Injection of human mesenchymal stem cells improves healing of vocal folds after scar excision--a xenograft analysis
Svensson B, Nagubothu Sr, Cedervall J, Chan Rw, Le Blanc K, Kimura M, et al
The Laryngoscope 2011;121(10):2185-90

Is there a graft-versus-MDS effect after haematopoietic allogeneic stem cell transplantation?
Remberger M, Mattsson J, Hassan Z, Hagglund H, Le Blanc K, Machaczka M, et al
BONE MARROW TRANSPLANTATION 2011;:S369-S369

Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages
Ringden O, Le Blanc K
Best practice & research. Clinical haematology 2011;24(1):65-72

Mesenchymal stromal cells are highly effective in steroid-refractory, grade III-IV acute graft-versus-host disease in children
Ball Lm, Bernardo Me, Van Tol Mjd, Giorgiani G, Roelofs H, Cometa Am, et al
BONE MARROW TRANSPLANTATION 2011;:S6-S7

Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses
Moll G, Jitschin R, Von Bahr L, Rasmusson-duprez I, Sundberg B, Lonnies L, et al
PloS one 2011;6(7):e21703-

Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity?
Sundin M, D'arcy P, Johansson Cc, Barrett Aj, Lonnies H, Sundberg B, et al
Journal of immunotherapy (Hagerstown, Md. : 1997) 2011;34(4):336-42

Pooled MSCs for treatment of severe hemorrhage
Ringden O, Leblanc K
Bone marrow transplantation 2011;46(8):1158-60

The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells
Mougiakakos D, Jitschin R, Johansson Cc, Okita R, Kiessling R, Le Blanc K
Blood 2011;117(18):4826-35

Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study
Jungebluth P, Alici E, Baiguera S, Blomberg P, Bozoky B, Crowley C, et al
Lancet (London, England) 2011;378(9808):1997-2004

Children responding to treatment with mesenchymal stromal cells for refractory severe graft-versus-host disease have excellent long-term outcome
Ball Lm, Bernardo Me, Van Tol Mjd, Avanzini Ma, Lankester Ac, Roelofs H, et al
BONE MARROW TRANSPLANTATION 2010;:S261-S261

Concise review: hitting the right spot with mesenchymal stromal cells
Tolar J, Le Blanc K, Keating A, Blazar Br
Stem cells (Dayton, Ohio) 2010;28(8):1446-55

Defining the risks of mesenchymal stromal cell therapy
Prockop Dj, Brenner M, Fibbe We, Horwitz E, Le Blanc K, Phinney Dg, et al
Cytotherapy 2010;12(5):576-8

Early Intervention with Mesenchymal Stromal Cells for Refractory Grade III-IV Graft Versus Host Disease In Children Results In Excellent Long Term Outcome.
Ball Lm, Bernardo Me, Zwaginga Jj, Van Tol M, Cometa A, Roelofs H, et al
BLOOD 2010;116(21):965-965

Fuzzy uncertainty modeling for grid based localization of mobile robots
Herrero-perez D, Martinez-barbera H, Leblanc K, Saffiotti A
INTERNATIONAL JOURNAL OF APPROXIMATE REASONING 2010;51(8):912-932

Genetically Engineered Cells Target CNS and Cure Experimental Autoimmune Encephalomyelitis
Fransson M, Piras E, Wang H, Duprez Ir, Leblanc K, Brittebo E, et al
HUMAN GENE THERAPY 2010;21(10):1381-1381

Human Embryonic Stem Cell-Derived Mesenchymal Stroma Cells (hES-MSC) Share Basic Properties with Bone Marrow MSC, They Have Potent Stroma Support Capacities but Lack Immune-Modulatory Function. Implications for off-the Shelf ES-MSC Therapies
Li O, Tormin A, Brune Jc, Sundberg B, Hyllner J, Le Blanc K, et al
BLOOD 2010;116(21):1578-1578

Immunotherapy prospects for acute myeloid leukaemia
Barrett Aj, Le Blanc K
Clinical and experimental immunology 2010;161(2):223-32

Injection of human mesenchymal stem cells improves healing of scarred vocal folds: analysis using a xenograft model
Svensson B, Nagubothu Rs, Cedervall J, Le Blanc K, Ahrlund-richter L, Tolf A, et al
The Laryngoscope 2010;120(7):1370-5

Photochemical pathogen inactivation of human serum enables its large-scale application in clinical cell transplantation
Stahle M, Carlsson B, Le Blanc K, Korsgren O, Knutson F
Vox sanguinis 2010;98(3 Pt 1):e364-5

The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group
Freedman Ms, Bar-or A, Atkins Hl, Karussis D, Frassoni F, Lazarus H, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2010;16(4):503-10

Basic research and clinical applications of non-hematopoietic stem cells, 4-5 April 2008, Tubingen, Germany
Schafer R, Dominici M, Muller I, Horwitz E, Asahara T, Bulte Jw, et al
Cytotherapy 2009;11(2):245-55

CMV infection and disease after allogeneic stem cell transplantation with reduced-intensity conditioning
Avetisyan G, Hagglund H, Hassan Z, Leblanc K, Mattsson J, Ringden O, et al
BONE MARROW TRANSPLANTATION 2009;:S241-S242

Complement compatibility of human mesenchymal stem cells during clinical infusion into whole blood for treatment of graft-versus-host disease
Moll G, Rasmusson I, Elgue G, Sundberg B, Ekdahl Kn, Le Blanc K, et al
BONE MARROW TRANSPLANTATION 2009;:S161-S162

Endovascular transplantation of stem cells to the injured rat CNS
Lundberg J, Le Blanc K, Soderman M, Andersson T, Holmin S
Neuroradiology 2009;51(10):661-7

HLA MISMATCHED MSC SUPPRESS T LYMPHOCYTE ALLORESPONSES IN VITRO AND DO NOT INDUCE IMMUNOLOGICAL MEMORY IN RECIPIENTS OF MSC INFUSION
Sundin M, Barrett J, Ringden O, Uzunel M, Lonnies H, Dackland Al, et al
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 2009;15(2):47-47

HSCT recipients have specific tolerance to MSC but not to the MSC donor
Sundin M, Barrett Aj, Ringden O, Uzunel M, Lonnies H, Dackland Al, et al
Journal of immunotherapy (Hagerstown, Md. : 1997) 2009;32(7):755-64

Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies
Le Blanc K, Barrett Aj, Schaffer M, Hagglund H, Ljungman P, Ringden O, et al
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2009;15(9):1108-15

LYMPHOCYTE RECOVERY IS A MAJOR DETERMINANT OF TRANSPLANT OUTCOME AFTER MYELOABLATIVE TRANSPLANTATION IN PATIENTS WITH MYELOID MALIGNANCIES RECEIVING MATCHED UNRELATED STEM CELL ALLOGRAFTS
Le Blanc K, Remberger M, Barrett J
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 2009;15(2):12-13

Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells
Samuelsson H, Ringden O, Lonnies H, Le Blanc K
Cytotherapy 2009;11(2):129-36

SCT recipients have specific tolerance to MSC but not to the MSC donor
Sundin M, Barrett J, Ringden O, Uzunel M, Lonnies H, Dackland A, et al
BONE MARROW TRANSPLANTATION 2009;:S188-S188

Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction
Omar H, Hagglund H, Gustafsson-jernberg A, Leblanc K, Mattsson J, Remberger M, et al
Transplant infectious disease : an official journal of the Transplantation Society 2009;11(5):393-9

A new cell therapy registry coordinated by the European Group for Blood and Marrow Transplantation (EBMT)
Le Blanc K, Fibbe W
Bone marrow transplantation 2008;41(3):319-

EBV associated PTLD after allogeneic stem cell transplant patients
Omar H, Hagglund H, Gustafsson-jernberg A, Le Blanc K, Mattsson J, Remberger M, et al
BONE MARROW TRANSPLANTATION 2008;:S60-S60

In vitro immunologic properties of human umbilical cord perivascular cells
Ennis J, Gotherstrom C, Le Blanc K, Davies Je
Cytotherapy 2008;10(2):174-81

Lymphocyte recovery: an overlooked contribution to autologous stem cell transplant outcome
Le Blanc K
Cytotherapy 2008;10(5):441-2

Lymphocyte recovery is a major determinant of transplant outcome after myeloablative transplantation in patients with myeloid malignancies receiving matched unrelated grafts
Le Blanc K, Remberger M, Barrett J
BONE MARROW TRANSPLANTATION 2008;:S11-S12

Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses
Karlsson H, Samarasinghe S, Ball L, Sundberg B, Lankester Ac, Dazzi F, et al
BONE MARROW TRANSPLANTATION 2008;:S15-S16

Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses
Karlsson H, Samarasinghe S, Ball Lm, Sundberg B, Lankester Ac, Dazzi F, et al
Blood 2008;112(3):532-41

MESENCHYMAL STEM CELLS EXERT DIFFERENTIAL EFFECTS ON ALLO-ANTIGEN- AND VIRUS-SPECIFIC T CELLS
Karlsson H, Samarasinghe S, Ball L, Sundberg B, Lankester Ac, Dazzi F, et al
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 2008;14(2):48-49

Mesenchymal stem cells for acute graft-versus-host disease - Reply
Le Blanc K, Fibbe W, Frassoni F, Locatelli F, Ringden O
LANCET 2008;372(9640):716-716

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study
Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al
Lancet (London, England) 2008;371(9624):1579-86

Mesenchymal stem cells (MSC) in immunotherapy
Blanc Kl
IMMUNOLOGY 2008;:25-25

No increased trapping of multipotent mesenchymal stromal cells in bone marrow filters compared with other bone marrow cells
Sundin M, Remberger M, Lonnies H, Sundberg B, Ringden O, Le Blanc K
Cytotherapy 2008;10(3):238-42

Persistence of human parvovirus B19 in multipotent mesenchymal stromal cells expressing the erythrocyte P antigen: implications for transplantation
Sundin M, Lindblom A, Orvell C, Barrett J, Sundberg B, Watz E, et al
BONE MARROW TRANSPLANTATION 2008;:S322-S322

Persistence of human parvovirus B19 in multipotent mesenchymal stromal cells expressing the erythrocyte P antigen: implications for transplantation
Sundin M, Lindblom A, Orvell C, Barrett Aj, Sundberg B, Watz E, et al
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2008;14(10):1172-9

Prophylaxis of acute GVHD: manipulate the graft or the environment?
Barrett Aj, Le Blanc K
Best practice & research. Clinical haematology 2008;21(2):165-76

Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study
Remberger M, Mattsson J, Hassan Z, Karlsson N, Leblanc K, Omazic B, et al
Bone marrow transplantation 2008;41(4):399-405

Concise review: cancer/testis antigens, stem cells, and cancer
Costa Ff, Le Blanc K, Brodin B
Stem cells (Dayton, Ohio) 2007;25(3):707-11

Co-transplantation of mesenchymal stem cells and hematopoietic stem cells
Le Blanc K, Sundberg B, Lonnies H, Aschan J, Barkbolt L, Gustafsson B, et al
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 2007;13(2):46-46

Co-transplantation of parental mesenchymal stem cells to improve outcome of cord blood transplantation in children
Bernardo Me, Ball L, Cometa A, Zecca M, Giorgiani G, Maccario R, et al
BONE MARROW TRANSPLANTATION 2007;:S52-S52

Generation of immunosuppressive mesenchymal stem cells in allogeneic human serum
Le Blanc K, Samuelsson H, Lonnies L, Sundin M, Ringden O
Transplantation 2007;84(8):1055-9

Hemorrhagic cystitis: a retrospective single-center survey
Hassan Z, Remberger M, Svenberg P, Elbander M, Omazic B, Mattsson J, et al
Clinical transplantation 2007;21(5):659-67

Immunomodulation by mesenchymal stem cells and clinical experience
Le Blanc K, Ringden O
Journal of internal medicine 2007;262(5):509-25

Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005
Tyndall A, Walker Ua, Cope A, Dazzi F, De Bari C, Fibbe W, et al
Arthritis research & therapy 2007;9(1):301-

Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes
Rasmusson I, Uhlin M, Le Blanc K, Levitsky V
Journal of leukocyte biology 2007;82(4):887-93

Mesenchymal stem cells (MSCs) in immunotherapy
Le Blanc K
XENOTRANSPLANTATION 2007;14(5):426-427

Mesenchymal stem cells stimulate antibody secretion in human B cells
Rasmusson I, Le Blanc K, Sundberg B, Ringden O
Scandinavian journal of immunology 2007;65(4):336-43

No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients
Sundin M, Ringden O, Sundberg B, Nava S, Gotherstrom C, Le Blanc K
Haematologica 2007;92(9):1208-15

Progress in characterization, preparation and clinical applications of non-hematopoietic stem cells, 29-30 September 2006, Tübingen, Germany
Schafer R, Dominici M, Muller I, Dazzi F, Bieback K, Godthardt K, et al
Cytotherapy 2007;9(4):397-405

Prospecitve quantitative PCR monitoring of allogeneic stem cell transplant (SCT) patients at high risk for EBV associated PTLD
Omar H, Hagglund H, Gustafsson-jernberg A, Le Blanc K, Mattson J, Remberger M, et al
BLOOD 2007;110(11):872A-872A

Tissue repair using allogeneic mesenchymal stem cells for haemorrhagic cystitis, pneumomediastinum and perforated colon
Ringden O, Uzunel M, Sundberg B, Lonnies L, Nava S, Gustafsson J, et al
BONE MARROW TRANSPLANTATION 2007;:S219-S219

Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon
Ringden O, Uzunel M, Sundberg B, Lonnies L, Nava S, Gustafsson J, et al
Leukemia 2007;21(11):2271-6

Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon
Ringden O, Uzunel M, Sundberg B, Lonnies L, Nava S, Gotherstrom C, et al
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 2007;13(2):47-47

Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells
Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, et al
Leukemia 2007;21(8):1733-8

Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single center
Ringden O, Remberger M, Svahn Bm, Barkholt L, Mattsson J, Aschan J, et al
Transplantation 2006;81(5):718-25

Co-transplantation of haploidentical bone marrow-derived mesenchymal stem cells and haematopoietic stem cells to promote engraftment in children. A phase I/II multicentre study
Ball Lm, Le Blanc K, Roelofs H, Lankester A, Egeler Rm, Frassoni F, et al
BONE MARROW TRANSPLANTATION 2006;:S151-S151

Co-transplantation of haplo-identical bone marrow-derived mesenchymal stem cells and hematopoietic stem cells to promote engraftment in children. A phase I/II multicenter study.
Ball Lm, Leblanc K, Roelofs H, Lankester Ac, Egeler M, Frassoni F, et al
CYTOTHERAPY 2006;:-

Differences between human fetal and adult multipotent mesenchymal stromal cells (MSC) concerning NK-cell lysis.
Gotherstrom C, Rasmusson I, Le Blanc K
CYTOTHERAPY 2006;:-

Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens
Merup M, Lazarevic V, Nahi H, Andreasson B, Malm C, Nilsson L, et al
British journal of haematology 2006;135(3):367-73

Factors associated with relapse in patients with chronic graft-versus-host disease after allogeneic stem cell transplantation
Remberger M, Aschan J, Barkholt L, Hassan Z, Leblanc K, Mattsson J, et al
BONE MARROW TRANSPLANTATION 2006;:S104-S104

Herpesviruses in mesenchymal stem cells.
Sundin M, Orvell C, Rasmusson I, Sundberg B, Ringden O, Leblanc K
CYTOTHERAPY 2006;:-

Human mesenchymal stem cells do not differentiate into cardiomyocytes in a cardiac ischemic xenomodel
Grinnemo Kh, Mansson-broberg A, Leblanc K, Corbascio M, Wardell E, Siddiqui Aj, et al
Annals of medicine 2006;38(2):144-53

Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual
Sundin M, Orvell C, Rasmusson I, Sundberg B, Ringden O, Le Blanc K
Bone marrow transplantation 2006;37(11):1051-9

Mesenchymal stem cells combined with cyclosporine inhibits cytotoxic T cells
Ringden O, Le Blanc K
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2006;12(6):693-4

Mesenchymal stem cells for treatment of severe acute and extensive chronic graft-versus-host disease
Ringden O, Frassoni F, Uzunel M, Lanino E, Sundberg B, Lonnies H, et al
BONE MARROW TRANSPLANTATION 2006;:S1-S1

Mesenchymal stem cells for treatment of severe acute graft-versus-host disease
Ringden O, Uzunel M, Rasmusson I, Remberger Me, Sundberg B, Lonnies H, et al
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 2006;12(2):2-2

Mesenchymal stem cells for treatment of severe acute graft-versus-host disease.
Le Blanc K, Frassoni F, Ball L, Lanino E, Sundberg B, Lonnies L, et al
BLOOD 2006;108(11):226A-226A

Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease
Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, et al
Transplantation 2006;81(10):1390-7

Mesenchymal stem cells (MSCS) in immunotherapy
Le Blanc K
ANNALS OF ONCOLOGY 2006;:25-26

Mesenchymal stem cells (MSCS) in immunotherapy
Le Blanc K
EXPERIMENTAL HEMATOLOGY 2006;34(9):65-65

Mesenchymal stem cells: properties and role in clinical bone marrow transplantation
Le Blanc K, Ringden O
Current opinion in immunology 2006;18(5):586-91

Mesenchymal stromal cells: Tissue repair and immune modulation
Le Blanc K
Cytotherapy 2006;8(6):559-61

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement
Dominici M, Le Blanc K, Mueller I, Slaper-cortenbach I, Marini F, Krause D, et al
Cytotherapy 2006;8(4):315-7

Myeloablative conditioning for hematopoietic stem-cell transplantation in patients with non-malignant diseases
Ringden O, Svenberg P, Le Blanc K, Mattsson J, Remberger M
Bone marrow transplantation 2006;38(4):321-2

Optimized in vitro conditions for immunomodulation by adult mesenchymal stem cells.
Ringden O, Lonnies L, Le Blanc K
CYTOTHERAPY 2006;:-

Stem cells and rheumatology: update on adult stem cell therapy in autoimmune diseases
Tyndall A, Leblanc K
Arthritis and rheumatism 2006;55(4):521-5

The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation
Sundin M, Le Blanc K, Ringden O, Barkholt L, Omazic B, Lergin C, et al
Haematologica 2006;91(8):1059-67

Viscoelastic and histologic properties in scarred rabbit vocal folds after mesenchymal stem cell injection
Hertegard S, Cedervall J, Svensson B, Forsberg K, Maurer Fh, Vidovska D, et al
The Laryngoscope 2006;116(7):1248-54

Allogeneic haematopoietic stem cell transplantation for metabolic disorders, a single-centre experience
Ringden O, Remberger M, Svahn B, Barkholt L, Aschan J, Mattsson J, et al
BONE MARROW TRANSPLANTATION 2005;:S267-S267

Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives
Ringden O, Le Blanc K
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2005;113(11-12):813-30

Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression
Cronwright G, Le Blanc K, Gotherstrom C, Darcy P, Ehnman M, Brodin B
Cancer research 2005;65(6):2207-15

Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement
Horwitz Em, Le Blanc K, Dominici M, Mueller I, Slaper-cortenbach I, Marini Fc, et al
Cytotherapy 2005;7(5):393-5

Cyclosporine A (CsA) 2 hour-concentration after oral intake varies between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation
Barkholt L, Bottiger Y, Bodegard H, Elbander M, Aschan J, Hassan Z, et al
BONE MARROW TRANSPLANTATION 2005;:S145-S146

Difference in gene expression between human fetal liver and adult bone marrow mesenchymal stem cells
Gotherstrom C, West A, Liden J, Uzunel M, Lahesmaa R, Le Blanc K
Haematologica 2005;90(8):1017-26

Differential function of the alpha2A-adrenoceptor and Phosphodiesterase-3B in human adipocytes of different origin
Dicker A, Kaaman M, Van Harmelen V, Astrom G, Blanc Kl, Ryden M
International journal of obesity (2005) 2005;29(12):1413-21

Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta
Le Blanc K, Gotherstrom C, Ringden O, Hassan M, Mcmahon R, Horwitz E, et al
Transplantation 2005;79(11):1607-14

Functional studies of mesenchymal stem cells derived from adult human adipose tissue
Dicker A, Le Blanc K, Astrom G, Van Harmelen V, Gotherstrom C, Blomqvist L, et al
Experimental cell research 2005;308(2):283-90

Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: uses, misuses, misconceptions, and future applications
Ringden Ot, Le Blanc K, Remberger M
Experimental hematology 2005;33(5):505-12

Human mesenchymal stem cells affect IgG production induced by lipopolysaccharide, cytomegalovirus and varicella zoster virus in human spleen
Rasmusson I, Sundberg B, Le Blanc K, Ringden O
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 2005;11(2):69-70

Human mesenchymal stem cells do not differentiate into cardiac myocytes in ischaemic myocardium
Grinnemo Kh, Mansson-broberg A, Leblanc K, Siddiqui Aj, Hao X, Sylven C, et al
EUROPEAN HEART JOURNAL 2005;:685-685

Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation
Le Blanc K, Ringden O
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2005;11(5):321-34

Mesenchymal stem cells for treatment of severe acute and extensive chronic graft-versus-host disease.
Le Blanc K, Frassoni F, Ball L, Uzunel M, Lanini E, Sundberg B, et al
BLOOD 2005;106(11):45A-45A

Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms
Rasmusson I, Ringden O, Sundberg B, Le Blanc K
Experimental cell research 2005;305(1):33-41

Mesenchymal stem cells: progress toward promise
Le Blanc K, Pittenger M
Cytotherapy 2005;7(1):36-45

Transplantation of haplo-identical bone marrow-derived mesenchymal stem cells together with hematopoietic stem cells to promote engraftment in children - A phase I/II multicenter study
Van Velzen-ball Lm, Le Blanc K, Lankester Ac, Roelofs H, Egeler M, Frassoni F, et al
BLOOD 2005;106(11):817A-817A

Use of mesenchymal stem cells for the prevention of immune complications of hematopoietic stem cell transplantation
Le Blanc K, Ringden O
Haematologica 2005;90(4):438-

A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation
Le Blanc K, Remberger M, Uzunel M, Mattsson J, Barkholt L, Ringden O
Transplantation 2004;78(7):1014-20

A comparison of non-myeloablative versus reduced conditioning for allogeneic stem cell transplantation
Ringden O, Le Blanc K, Uzunel M, Mattsson J, Barkholt L, Remberger M
BONE MARROW TRANSPLANTATION 2004;:S38-S38

Allogenic stem cell transplantation for nonmalignant disorders using matched unrelated donors
Svenberg P, Remberger M, Svennilson J, Mattsson J, Leblanc K, Gustafsson B, et al
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2004;10(12):877-82

Graft-versus-host disease is associated with a lower relapse incidence after haematopoietic stem cell transplantation in patients with acute lymphoblastic leukaemia
Nordlander A, Mattsson J, Ringden O, Le Blanc K, Gustavsson B, Ljungman P, et al
BONE MARROW TRANSPLANTATION 2004;:S187-S187

Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia
Nordlander A, Mattsson J, Ringden O, Leblanc K, Gustafsson B, Ljungman P, et al
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2004;10(3):195-203

Human mesenchymal stem cells as a renewable source of adipocytes
Ryden M, Dicker A, Astrom G, Le Blanc K, Arner P
INTERNATIONAL JOURNAL OF OBESITY 2004;:S11-S11

Human mesenchymal stem cells increase interleukin-2 and soluble IL-2 receptor in mixed lymphocyte cultures
Rasmusson I, Ringden O, Sundberg B, Lonnies L, Le Blanc K
BONE MARROW TRANSPLANTATION 2004;:S87-S87

Immunological properties of human foetal mesenchymal stem cells
Gotherstrom C, Ringden O, Tammik C, Zetterberg E, Westgren M, Le Blanc K
BONE MARROW TRANSPLANTATION 2004;:S88-S89

Immunologic properties of human fetal mesenchymal stem cells
Gotherstrom C, Ringden O, Tammik C, Zetterberg E, Westgren M, Le Blanc K
American journal of obstetrics and gynecology 2004;190(1):239-45

Mesenchymal stem cell engraftment in bone following in utero transplantation in a patient with severe osteogenesis imperfecta.
Le Blanc K, Gotherstrom C, Ringden O, Hassan M, Mcmahon R, Horwitz E, et al
BLOOD 2004;104(11):147A-147A

Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes
Le Blanc K, Rasmusson I, Gotherstrom C, Seidel C, Sundberg B, Sundin M, et al
Scandinavian journal of immunology 2004;60(3):307-15

Mesenchymal stem cells inhibit the expression of IL-2 receptor (CD25) and CD38 on phytohemagglutinin-activated lymphocytes
Le Blanc K, Rasmusson I, Gotherstrom C, Seidel C, Sundberg B, Rosendahl K, et al
BONE MARROW TRANSPLANTATION 2004;:S86-S86

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al
Lancet (London, England) 2004;363(9419):1439-41

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al
BONE MARROW TRANSPLANTATION 2004;:S185-S185

Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death
Ringden O, Labopin M, Gorin Nc, Le Blanc K, Rocha V, Gluckman E, et al
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 2004;10(2):17-17

Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Ringden O, Labopin M, Gorin Nc, Le Blanc K, Rocha V, Gluckman E, et al
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(3):416-23

Which donor should be chosen for haematopoietic stem cell transplantation among unrelated HLA-A, -B and -DRB1 genomically identical volunteers?
Ringden O, Schaffer M, Le Blanc K, Persson U, Hauzenberger D, Abedi M, et al
BONE MARROW TRANSPLANTATION 2004;:S131-S132

Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?
Ringden O, Schaffer M, Le Blanc K, Persson U, Hauzenberger D, Abedi Mr, et al
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2004;10(2):128-34

Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium
Grinnemo Kh, Mansson A, Dellgren G, Klingberg D, Wardell E, Drvota V, et al
The Journal of thoracic and cardiovascular surgery 2004;127(5):1293-300

A low body mass index is correlated with poor survival after allogeneic stem cell transplantation
Le Blanc K, Ringden O, Remberger M
Haematologica 2003;88(9):1044-52

Donor chimerism across full allogenic barriers achieved by in utero transplantation of fetal mesenchymal stem cells in a case of osteogenesis imperfecta
Westgren L, Anneren G, Axelsson O, Evald U, Leblanc K, Ringden O
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 2003;189(6):S215-S215

Functional characterization of human mesenchymal stem cell-derived adipocytes
Ryden M, Dicker A, Gotherstrom C, Astrom G, Tammik C, Arner P, et al
Biochemical and biophysical research communications 2003;311(2):391-7

G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV
Remberger M, Naseh N, Aschan J, Barkholt L, Leblanc K, Svennberg P, et al
Bone marrow transplantation 2003;32(2):217-23

HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells
Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O
Experimental hematology 2003;31(10):890-6

Immunomodulatory effects of fetal and adult mesenchymal stem cells
Le Blanc K
Cytotherapy 2003;5(6):485-9

Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells
Gotherstrom C, Ringden O, Westgren M, Tammik C, Le Blanc K
Bone marrow transplantation 2003;32(3):265-72

Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex
Le Blanc K, Tammik L, Sundberg B, Haynesworth Se, Ringden O
Scandinavian journal of immunology 2003;57(1):11-20

Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells
Rasmusson I, Ringden O, Sundberg B, Le Blanc K
Transplantation 2003;76(8):1208-13

Transplantation of embryonic stem cells: possibilities and challenges
Ringden O, Le Blanc K, Hovatta O
Transplantation 2003;76(7):1011-2

Down-regulation of IMP-dehydrogenase and depletion of guanine ribonucleotides serve as metabolic signals for myeloid cell development.
Wright Dg, Le Blanc K, Boosalis M, Heckathorne R
BLOOD 2001;98(11):105A-106A

Inhibition or enhancement of mixed lymphocyte cultures by allogeneic and autologous mesenchymal stem cells is dependent on cell dose.
Le Blanc K, Tammik C, Sundberg B, Ringden O
BLOOD 2001;98(11):318B-318B

Defective platelet aggregation in polycythaemia vera is not caused by impaired calcium signaling, phospholipase D activation or decreased amounts of focal adhesion proteins
Le Blanc K, Berg A, Palmblad J, Samuelsson J
European journal of haematology 2000;65(5):322-30

Marked heterogeneity in protein levels and functional integrity of the thrombopoietin receptor c-mpl in polycythaemia vera
Le Blanc K, Andersson P, Samuelsson J
British journal of haematology 2000;108(1):80-5

Marked heterogeneity in protein levels and functional integrity of the thrombopoietin receptor c-mpl in polycythemia vera
Le Blanc K, Samuelsson J
THROMBOSIS AND HAEMOSTASIS 1999;:153-153

Defective platelet aggregation in polycythemia vera is not caused by impaired calcium signalling, phospholipase D activation or decreased amounts of FAK, SYK or rhoA.
Le Blanc K, Samuelsson J
BLOOD 1998;92(10):426A-426A

Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera
Le Blanc K, Lindahl T, Rosendahl K, Samuelsson J
Thrombosis research 1998;91(6):287-95

mRNA expression as well as protein levels of hematopoietic cell phosphatase are normal in both bone marrow CD34+ bone marrow progenitor cells and mature peripheral blood cells in polycythemia vera.
Andersson P, Leblanc K, Eriksson Ba, Samuelsson J
BLOOD 1997;90(10):4055-4055

No evidence for an altered mRNA expression or protein level of haematopoietic cell phosphatase in CD34+ bone marrow progenitor cells or mature peripheral blood cells in polycythaemia vera
Andersson P, Leblanc K, Eriksson Ba, Samuelsson J
European journal of haematology 1997;59(5):310-7

Elevated plasma lipoprotein (a) - A potential risk factor for thrombembolic complications in polycythemia vera.
Samuelsson J, Leblanc K
BLOOD 1996;88(10):3568-3568

Elevated plasma lipoprotein (a)--a potential risk factor for thromboembolic complications in polycythaemia vera
Leblanc K, Samuelsson J
European journal of haematology 1996;57(3):257-8

Impaired activation of the fibrinogen receptor on polycythemia vera platelets after platelet activating factor stimulation
Leblanc K, Lindahl T, Rosendahl K, Samuelsson J
BRITISH JOURNAL OF HAEMATOLOGY 1996;:625-625

1-O-hexadecyl-2-metoxy-glycero-3-phosphatidylcholine--a methoxy ether lipid inhibiting platelet activating factor-induced platelet aggregation and neutrophil oxidative metabolism
Le Blanc K, Samuelsson J, Brohult J, Berg A, Palmblad J
Biochemical pharmacology 1995;49(11):1577-82

1-O-HEXADECYL-2-METOXY-GLYCERO-3-PHOSPHATIDYLCHOLINE - A METHOXY ETHER LIPID INHIBITING PLATELET-ACTIVATING FACTOR-INDUCED PLATELET-AGGREGATION AND NEUTROPHIL OXIDATIVE-METABOLISM
Leblanc K, Samuelsson J, Brohult J, Berg A, Palmblad J
BIOCHEMICAL PHARMACOLOGY 1995;49(11):1577-1582

Visa alla publikationer